SCN8A: Sodium channel protein type 8 subunit alpha
Pore-forming subunit of a voltage-gated sodium channel complex assuming opened or closed conformations in response to the voltage difference across membranes and through which sodium ions selectively pass along their electrochemical gradient.
- Drugs that act on it: 1
- Approved: 0
- In phases 1 to 3: 1
- Sponsors: 0
Who is on it, and how far along
Every drug ChEMBL records acting on SCN8A, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 1
| Drug | Furthest stage | Sponsor | Modality | Action | Open trials |
|---|---|---|---|---|---|
| Zandatrigine | Phase 2 | — | Small molecule | InhibitorSodium channel protein type VIII alpha subunit inhibitor | 0 |
- Developmental and epileptic encephalopathy, 130.84
- Seizures, benign familial infantile, 50.77
- Seizure0.74
- Cognitive impairment with or without cerebellar ataxia0.73
- Epilepsy0.72
- Infantile epileptic encephalopathy0.68
- Undetermined early-onset epileptic encephalopathy0.67
- Genetic developmental and epileptic encephalopathy0.66
- Focal epilepsy0.66
- Complex neurodevelopmental disorder0.64
- Benign familial infantile epilepsy0.62
- Bipolar disorder0.61
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL5202, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-22. Gene name, function (UniProt Q9UQD0, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets